Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

作者
Chengfei Liu,Wei Lou,Yezi Zhu,Joy C. Yang,Nagalakshmi Nadiminty,Nilesh W. Gaikwad,Christopher P. Evans,Allen C. Gao
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:75 (7): 1413-1422 被引量:245
标识
DOI:10.1158/0008-5472.can-14-3080
摘要

The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer. However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study, we developed enzalutamide-resistant prostate cancer cells in an effort to understand the mechanisms of resistance. Global gene-expression analysis showed that the steroid biosynthesis pathway is activated in enzalutamide-resistant prostate cancer cells. One of the crucial steroidogenic enzymes, AKR1C3, was significantly elevated in enzalutamide-resistant cells. In addition, AKR1C3 is highly expressed in metastatic and recurrent prostate cancer and in enzalutamide-resistant prostate xenograft tumors. LC/MS analysis of the steroid metabolites revealed that androgen precursors such as cholesterol, DHEA and progesterone, as well as androgens are highly upregulated in enzalutamide-resistant prostate cancer cells compared to the parental cells. Knockdown of AKR1C3 expression by shRNA or inhibition of AKR1C3 enzymatic activity by indomethacin resensitized enzalutamide-resistant prostate cancer cells to enzalutamide treatment both in vitro and in vivo. In contrast, overexpression of AKR1C3 confers resistance to enzalutamide. Furthermore, the combination of indomethacin and enzalutamide resulted in significant inhibition of enzalutamide-resistant tumor growth. These results suggest that AKR1C3 activation is a critical resistance mechanism associated with enzalutamide resistance; targeting intracrine androgens and AKR1C3 will overcome enzalutamide resistance and improve survival of advanced prostate cancer patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhangzhangzhang完成签到 ,获得积分10
刚刚
津城以南完成签到,获得积分10
1秒前
林笙发布了新的文献求助10
1秒前
斯文败类的应助被拼搏的白玉采纳,获得10
1秒前
1秒前
远方发布了新的文献求助10
1秒前
远方发布了新的文献求助10
1秒前
远方发布了新的文献求助10
1秒前
远方发布了新的文献求助10
1秒前
星辰完成签到,获得积分10
1秒前
1秒前
1秒前
远方发布了新的文献求助10
1秒前
远方发布了新的文献求助10
1秒前
远方发布了新的文献求助10
1秒前
刘子田发布了新的文献求助10
2秒前
冷暴力完成签到,获得积分20
2秒前
2秒前
369ninja发布了新的文献求助10
2秒前
等等完成签到,获得积分20
2秒前
illuminate发布了新的文献求助10
2秒前
霸波儿奔完成签到,获得积分10
2秒前
3秒前
礐嶨发布了新的文献求助10
3秒前
专注路灯完成签到,获得积分20
3秒前
3秒前
自觉黑米完成签到,获得积分10
3秒前
情怀的应助被伊莎贝拉采纳,获得10
3秒前
4秒前
冷暴力发布了新的文献求助10
4秒前
阳光飞瑶完成签到,获得积分10
4秒前
CodeCraft的应助被xkr采纳,获得10
5秒前
隐形曼青的应助被甜美无剑采纳,获得10
5秒前
5秒前
小蘑菇的应助被江江采纳,获得20
5秒前
FashionBoy的应助被挽风风风风采纳,获得10
5秒前
等等发布了新的文献求助10
5秒前
null的应助被还见似帝尧采纳,获得10
6秒前
包容煎饼发布了新的文献求助30
6秒前
lsx发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315